comparemela.com

Latest Breaking News On - Prnewswire neurosense therapeutics ltd - Page 7 : comparemela.com

NEUROSENSE THERAPEUTICS LTD TO PARTICIPATE IN RENMARK S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc. s live.

United kingdomNedira salzman frenkelRenmark financial communications incPrnewswire neurosense therapeutics ltdCompany investorBusiness developmentNeurosense therapeutics ltdSense therapeuticsRenmark financial communicationsVirtual non deal roadshow seriesAlon ben noonChief executive officerNeurosense and renmark financial communications inc

NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesUnited kingdomFerenc tracikGermany federal institute for drugsPrnewswire neurosense therapeutics ltdDrug administrationNeurosense therapeutics ltdCompany clinical trial applicationEuropean medicines agencySense therapeuticsFederal instituteMedical devicesClinical trial applicationChief medical officerMassachusetts general hospitalNeuron derived exosomes

NeuroSense Therapeutics Reports Positive Final Results from Alzheimer s Biomarker Study

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomPrnewswire neurosense therapeutics ltdNeurosense therapeutics ltdSense therapeutics

NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomLoma linda universityUnited statesSan franciscoNiva russekJeremy shefnerJeffrey rosenfeldCharles duncanFerenc tracikShiran zimriNedira salzman frenkelAmyotrophic lateral sclerosis consortiumNeurosense head of the scientific programCompany investigational new drugPrnewswire neurosense therapeutics ltdDrug administration

NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesUnited kingdomCompany phasePrnewswire neurosense therapeutics ltdDrug administrationNeurosense therapeutics ltdEuropean medicines agencyItalian medicines agencySense therapeuticsMassachusetts general hospitalNeuron derived exosomesOrphan drug designation

vimarsana © 2020. All Rights Reserved.